Parametric Portfolio Associates LLC lessened its holdings in Allergan PLC. (NYSE:AGN) by 1.0% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 601,460 shares of the company’s stock after selling 6,246 shares during the quarter. Parametric Portfolio Associates LLC owned 0.18% of Allergan worth $123,269,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in AGN. Howard Hughes Medical Institute bought a new stake in Allergan during the second quarter worth about $103,000. Cable Hill Partners LLC lifted its position in Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares during the period. Rockefeller Financial Services Inc. lifted its position in Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares during the period. Massey Quick & Co. LLC lifted its position in Allergan by 334.8% during the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares during the period. Finally, Pacific Center for Financial Services lifted its position in Allergan by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after purchasing an additional 7 shares during the period. 81.34% of the stock is owned by institutional investors.
In other news, insider William Meury sold 11,807 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Brent L. Saunders acquired 4,600 shares of the stock in a transaction dated Wednesday, December 6th. The stock was purchased at an average cost of $164.74 per share, with a total value of $757,804.00. The disclosure for this purchase can be found here. Insiders bought 17,630 shares of company stock valued at $2,890,057 in the last ninety days. 0.36% of the stock is currently owned by insiders.
Allergan PLC. (NYSE AGN) opened at $171.68 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. The company has a market capitalization of $56,851.75, a PE ratio of 11.09, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11. Allergan PLC. has a 52 week low of $160.07 and a 52 week high of $256.80.
Allergan (NYSE:AGN) last issued its earnings results on Wednesday, November 1st. The company reported $4.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The business’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.32 earnings per share. sell-side analysts forecast that Allergan PLC. will post 16.27 EPS for the current year.
Allergan declared that its board has initiated a stock buyback plan on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently announced a quarterly dividend, which was paid on Friday, December 15th. Shareholders of record on Friday, November 17th were paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 1.63%. The ex-dividend date of this dividend was Thursday, November 16th. Allergan’s payout ratio is -12.44%.
Several equities research analysts recently weighed in on AGN shares. Cantor Fitzgerald reaffirmed a “hold” rating on shares of Allergan in a research report on Tuesday, August 22nd. BidaskClub cut shares of Allergan from a “sell” rating to a “strong sell” rating in a research report on Friday, August 25th. Cowen reaffirmed an “outperform” rating and set a $400.00 price objective on shares of Allergan in a research report on Tuesday, August 29th. Royal Bank of Canada reaffirmed a “buy” rating and set a $285.00 price objective on shares of Allergan in a research report on Wednesday, September 6th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating on shares of Allergan in a research report on Monday, September 11th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $235.25.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2017/12/16/parametric-portfolio-associates-llc-sells-6246-shares-of-allergan-plc-agn.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.